Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 28, 2026 07:00 ET | Source: Trogenix

Trogenix doses first patient in Phase I/II clinical trial of TGX-007 gene therapy for glioblastoma

UK and US trial sites open; first patient dosed with TGX-007, Trogenix’s proprietary dual-payload AAV gene therapyTGX-007 leverages Trogenix’s precision synthetic super-enhancer platform that...
May 28, 2026 07:00 ET | Source: BPGbio

BPGbio to Present Ongoing Phase 2 Study Trial-in-Progress Update of BPM31510 in Newly Diagnosed Glioblastoma at ASCO 2026

BPM31510 is a first-in-class therapeutic targeting tumor metabolism to re-program mitochondrial microenvironment in Warburg-avid tumorsBoth safety profile and efficacy data to be highlighted in...
May 28, 2026 02:00 ET | Source: Trogenix

Trogenix doses first patient in Phase I/II clinical trial of TGX-007 gene therapy for glioblastoma

UK and US trial sites open; first patient dosed with TGX-007, Trogenix’s proprietary dual-payload AAV gene therapyTGX-007 leverages Trogenix’s precision synthetic super-enhancer platform that...
May 27, 2026 13:00 ET | Source: DelveInsight Business Research LLP

Glioblastoma Multiforme Market Poised for Significant Growth at a CAGR of 13.2% During the Forecast Period (2026–2036), as Next-Generation Therapies Enter Late-Stage Development | DelveInsight

New York, USA, May 27, 2026 (GLOBE NEWSWIRE) -- Glioblastoma Multiforme Market Poised for Significant Growth at a CAGR of 13.2% During the Forecast Period (2026–2036), as Next-Generation Therapies...
May 26, 2026 08:00 ET | Source: Brain Cancer Canada

Brain Cancer Canada Invests $50,000 in Promising Immunotherapy Breakthrough Targeting One of the Most Aggressive Brain Tumours

TORONTO, May 26, 2026 (GLOBE NEWSWIRE) -- Brain Cancer Canada (BCC), Canada’s only 100% volunteer-driven charity dedicated exclusively to funding brain cancer research nationwide is proud to award...
May 21, 2026 08:00 ET | Source: Brain Cancer Canada

Brain Cancer Canada Awards The Dwayne Andrews Glioblastoma Research Grant to Tackle One of the Most Aggressive Brain Tumours and Unlock Immunotherapy Breakthroughs for Young Patients

TORONTO, May 21, 2026 (GLOBE NEWSWIRE) -- Brain Cancer Canada (BCC), the country’s only 100% volunteer-driven charity dedicated exclusively to funding brain cancer research nationwide, is proud to...
May 19, 2026 08:00 ET | Source: Brain Cancer Canada

Brain Cancer Canada Invests $75,000 in Groundbreaking Glioblastoma Research at University of Alberta, Targeting How Tumours “Communicate”

TORONTO, May 19, 2026 (GLOBE NEWSWIRE) -- Brain Cancer Canada (BCC), Canada’s only 100% volunteer-driven charity dedicated exclusively to funding brain cancer research nationwide, is proud to award...
May 18, 2026 16:01 ET | Source: Alpha Tau Medical Ltd.

Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update

Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update
May 18, 2026 08:00 ET | Source: Provectus Biopharmaceuticals Inc.

Provectus Biopharmaceuticals Reports Oral PV-10 Anti-Tumor Activity in Preclinical Bladder Cancer Study; Long-Term Survivors Show Absence of Gross Bladder Tumor at Study End

Long-term survivors in both oral PV-10 arms showed an absence of gross bladder tumor at necropsy, a finding not observed in any untreated, vehicle-control, or anti-PD-1 monotherapy animal. KNOXVILLE,...
May 14, 2026 08:00 ET | Source: Brain Cancer Canada

Brain Cancer Canada Invests $75,000 in Groundbreaking Phase 2 Clinical Trial at Sunnybrook Health Sciences Centre to Target Hard-to-Treat Glioblastoma in Older Patients

TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Brain Cancer Canada (BCC), Canada’s only 100% volunteer-driven charity dedicated exclusively to funding brain cancer research nationwide to award $75,000 to...